ROCO
3118
Market cap32mUSD
Jul 08, Last price
31.70TWD
1D
-0.94%
1Q
-5.65%
Jan 2017
4.62%
IPO
-4.89%
Name
Level Biotechnology Inc
Chart & Performance
P/E
12.91
P/S
1.40
EPS
2.46
Div Yield, %
5.68%
Shrs. gr., 5y
0.04%
Rev. gr., 5y
1.84%
Revenues
737m
+0.72%
Net income
80m
+22.97%
CFO
60m
-7.00%
Dividend
Jun 12, 20251.8 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Level Biotechnology Inc., founded in 1989 and based in New Taipei City, Taiwan, operates in the commercialization and distribution of scientific products and services. The company supplies specialized reagents and consumables for cell culture, immunology, and molecular biology, alongside advanced biomedical instrumentation, throughout Taiwan. Beyond product distribution, Level Biotechnology offers a comprehensive suite of research and testing services. These include expert assessments in mammalian and genetic toxicology, pharmacological studies, biocompatibility testing, and the production of model animals. The firm's preclinical research capabilities serve a diverse range of clients in the biotechnology, pharmaceutical, medical device, animal health, and agrichemical industries.
IPO date
Sep 10, 2004
Employees
Domiciled in
TW
Incorporated in
TW
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||